中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(6): 1191-1195

Efficacy and safety of artificial liver support therapy with a selective plasma separator in low-platelet count patients with acute-on-chronic liver failure

DOI: 10.12449/JCH240619
  • a.

    Department of Hepatology,Chengdu Public Health Medical Center，Chengdu 610066，China

  • b.

    Center for Artificial Liver Support Therapy，Chengdu Public Health Medical Center，Chengdu 610066，China

Research funding:

Health Commission of Chengdu Municipality (2021435);

Chinese Public Health Alliance Project （first batch） (GWLM202037)

More Information
  • Corresponding author: LI Shoujuan， lishoujuan2005@126.com （ORCID： 0009⁃0000⁃6382⁃0346）
  • Received Date: 2023-08-07
  • Accepted Date: 2023-11-06
  • Published Date: 2024-06-25
    Abstract
  •   Objective  To investigate the efficacy and safety of artificial liver support therapy with an Evanure-4A selective membrane plasma separator and its influence on platelet count in the treatment of patients with acute-on-chronic liver failure （ACLF） patients with different platelet counts.  Methods  A total of 302 patients with ACLF who were hospitalized in Department of Hepatology， Chengdu Public Health Clinical Medical Center， from January 2021 to May 2023， were enrolled， and according to the platelet count （PLT）， they were divided into group A （25×109/L — 50×109/L） with 101 patients， group B （51×109/L — 80×109/L） with 98 patients， and group C （81×109/L — 100×109/L） with 103 patients. In addition to medical treatment， all patients received different modes of artificial liver support therapy based on their conditions， including plasma perfusion combined with plasma exchange， double plasma molecular adsorption combined with plasma exchange， and bilirubin system adsorption combined with plasma exchange. The paired t-test was used for comparison of continuous data before and after treatment in each group； an analysis of variance was used for comparison between multiple groups， and the SNK-q test was used for further comparison between two groups； the chi-square test was used for comparison of categorical data between multiple groups.  Results  Of all 302 patients， 268 （88.74%） achieved varying degrees of improvement in clinical symptoms after artificial liver support therapy. After treatment， all three groups had varying degrees of reductions in alanine aminotransferase （t=14.755， 21.614， and 15.965， all P<0.001）， aspartate aminotransferase （t=11.491， 19.301， and 13.919， all P<0.001）， total bilirubin （t=19.182， 17.486， and 21.75， all P<0.001）， and international normalized ratio （INR） （t=3.497， 3.327， and 4.358， all P<0.05）. After artificial liver support therapy with an Evanure-4A selective membrane plasma separator， PLT in group A decreased from （37.73±6.27）×109/L before treatment to （36.59±7.96）×109/L after treatment， PLT in group B decreased from （66.97±7.64）×109/L before treatment to （62.59±7.37）×109/L after treatment， and PLT in group C decreased from （93.82±5.38）×109/L before treatment to （85.99±12.49）×109/L after treatment； groups B and C had significant reductions in PLT after treatment （t=12.993 and 8.240， both P<0.001）， but there was no significant difference in group A （P>0.05）. There was no significant difference in the incidence rate of adverse reactions during artificial liver support therapy between the three groups （P>0.05）.  Conclusion  Artificial liver support therapy can improve liver function and INR in patients with ACLF. The use of Evaure-4A selective membrane plasma separator during artificial liver support therapy has little influence on platelets， and it is safe in the treatment of ACLF patients with a significantly lower level of platelets.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    ALLEN AM, KIM WR, MORIARTY JP, et al. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States[J]. Hepatology, 2016, 64( 6): 2165- 2172. DOI: 10.1002/hep.28812.
    [2]
    HUANG KZ, JI FY, XIE ZY, et al. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis[J]. Sci Rep, 2019, 9( 1): 16462. DOI: 10.1038/s41598-019-53029-0.
    [3]
    QIN G, BIAN ZL, SHEN Y, et al. Logistic regression model can reduce unnecessary artificial liver support in hepatitis B virus-associated acute-on-chronic liver failure: Decision curve analysis[J]. BMC Med Inform Decis Mak, 2016, 16: 59. DOI: 10.1186/s12911-016-0302-7.
    [4]
    YE JM, CHEN H, ZHU AF. Efficacy and safety of selective plasma exchange in patients with chronic severe hepatitis and severe thrombocytopenia[C]// Proceedings of the Third International and National Academic Conference on Liver Failure and Artificial Liver. 2005: 177- 179.

    叶俊茂, 陈红, 朱爱芬. 慢性重型肝炎伴严重血小板减少患者进行选择性血浆置换的效果和安全性研究[C]// 第三屇国际暨全国肝衰竭与人工肝学术会议论文集. 2005: 177- 179.
    [5]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [6]
    LI YW, ZHOU XY, ZOU CY. Application of plasma perfusion in refractory hyperbilirubinemia[J]. Natl Med Front China, 2011, 6( 5): 40. DOI: 10.3969/j.issn.1673-5552.2011.05.0021.

    李益文, 周晓颖, 邹春毅. 血浆灌流在难治型高胆红素血症中的应用研究[J]. 中国医疗前沿, 2011, 6( 5): 40. DOI: 10.3969/j.issn.1673-5552.2011.05.0021.
    [7]
    LI SJ, WANG L. To observe the efficacy of plasma exchange with plasma perfusion in treatment of chronic severe hepatitis B[J]. Sichuan Med J, 2014, 35( 11): 1472- 1474. DOI: 10.16252/j.cnki.issn1004-0501-2014.11.014.

    李守娟, 王丽. 血浆置换联合血浆灌流治疗慢性乙型重型肝炎疗效观察[J]. 四川医学, 2014, 35( 11): 1472- 1474. DOI: 10.16252/j.cnki.issn1004-0501-2014.11.014.
    [8]
    GARCIA-TSAO G. Acute-on-chronic liver failure: An old entity in search of clarity[J]. Hepatol Commun, 2018, 2( 12): 1421- 1424. DOI: 10.1002/hep4.1287.
    [9]
    CAI YF, WANG ZH, CHENG SQ. A comparative study of three non-biological artificial liver models in the treatment of patients with acute-on-chronic liver failure[J/OL]. Chin J Liver Dis(Electronic Version), 2023, 15( 1): 47- 55. DOI: 10.3969/j.issn.1674-7380.2023.01.008.

    蔡毅峰, 王朝辉, 程书权. 三种非生物型人工肝模式治疗慢加急性肝衰竭患者的对比研究[J/OL]. 中国肝脏病杂志(电子版), 2023, 15( 1): 47- 55. DOI: 10.3969/j.issn.1674-7380.2023.01.008.
    [10]
    ZHANG Z, ZHU J, DOU Y. Effect of artificial liver plasma exchange combined with CRRT in the treatment of hepatitis B-related chronic acute liver failure complicated with acute renal failure and its impact on prognosis[J]. Clin Misdiagn Misther, 2023, 36( 10): 86- 90. DOI: 10.3969/j.issn.1002-3429.2023.10.019.

    张泽, 朱健, 窦燕. 人工肝血浆置换联合CRRT治疗乙肝相关慢加急性肝衰竭合并急性肾衰竭效果及对预后的影响[J]. 临床误诊误治, 2023, 36( 10): 86- 90. DOI: 10.3969/j.issn.1002-3429.2023.10.019.
    [11]
    HARUKI K, SHIBA H, SAITO N, et al. Risk stratification using a novel liver functional reserve score of combination prothrombin time-international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma[J]. Surgery, 2018, 164( 3): 404- 410. DOI: 10.1016/j.surg.2018.02.022.
    [12]
    HU XP, GAO J. International normalized ratio and Model for End-stage Liver Disease score predict short-term outcome in cirrhotic patients after the resolution of hepatic encephalopathy[J]. World J Gastroenterol, 2019, 25( 26): 3426- 3437. DOI: 10.3748/wjg.v25.i26.3426.
    [13]
    O'LEARY JG, GREENBERG CS, PATTON HM, et al. AGA clinical practice update: Coagulation in cirrhosis[J]. Gastroenterology, 2019, 157( 1): 34- 43. DOI: 10.1053/j.gastro.2019.03.070.
    [14]
    YANG JY, GENG HZ, CHENG SQ, et al. Comparison on effects of three non-biological artificial liver methods in treatment of acute-on-chronic liver failure[J]. Chin J Integr Tradit West Med Intensive Crit Care, 2021, 38( 5): 574- 579. DOI: 10.3969/j.issn.1008-9691.2021.05.014.

    杨景毅, 耿宏智, 程书权, 等. 不同非生物人工肝治疗慢加急性肝功能衰竭的效果比较[J]. 中国中西医结合急救杂志, 2021, 38( 5): 574- 579. DOI: 10.3969/j.issn.1008-9691.2021.05.014.
    [15]
    LI SJ, WANG L, WU B, et al. Clinical observation of double plasma molecular adsorption system combined with plasma exchange in treatment of severe hepatitis B[J]. Clin Focus, 2015, 30( 7): 781- 784. DOI: 10.3969/j.issn.1004-583X.2015.07.013.

    李守娟, 王丽, 吴蓓, 等. 双重血浆吸附联合血浆置换治疗重型乙型肝炎的临床观察[J]. 临床荟萃, 2015, 30( 7): 781- 784. DOI: 10.3969/j.issn.1004-583X.2015.07.013.
    [16]
    LI SJ, WANG L, HU ZX, et al. Clinical observation of artificial liver combined with Liangxue Jiedu Huayu Fang on treatment of severe hepatitis B[J]. J Hunan Univ Chin Med, 2016, 36( 6): 20- 23. DOI: 10.3969/j.issn.1674-070X.2016.06.006.

    李守娟, 王丽, 胡朝霞, 等. 人工肝联合凉血解毒化瘀方治疗重型乙肝疗效观察[J]. 湖南中医药大学学报, 2016, 36( 6): 20- 23. DOI: 10.3969/j.issn.1674-070X.2016.06.006.
    [17]
    MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144( 7): 1426- 1437. DOI: 10.1053/j.gastro.2013.02.042.
    [18]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64( 4): 1249- 1264. DOI: 10.1002/hep.28740.
    [19]
    LUO L, YUAN CL. Comparative analysis of blood cell count and blood biochemistry after plasmapheresis with two kinds of membranous plasma separator[J]. World Chin J Dig, 2006, 14( 19): 1937- 1939. DOI: 10.3969/j.issn.1009-3079.2006.19.018.

    罗玲, 袁春兰. 两种膜分离器对血浆置换后血细胞数及血生化影响的比较[J]. 世界华人消化杂志, 2006, 14( 19): 1937- 1939. DOI: 10.3969/j.issn.1009-3079.2006.19.018.
    [20]
    WANG L, XU WX, ZHU S, et al. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 5): 1053- 1058. DOI: 10.3969/j.issn.1001-5256.2022.05.015.

    王璐, 许文雄, 朱姝, 等. 人工肝治疗HBV相关慢加急性肝衰竭的血小板计数变化及其影响因素[J]. 临床肝胆病杂志, 2022, 38( 5): 1053- 1058. DOI: 10.3969/j.issn.1001-5256.2022.05.015.
    [21]
    GHANY MG, LOK ASF, EVERHART JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C[J]. Gastroenterology, 2010, 138( 1): 136- 146. DOI: 10.1053/j.gastro.2009.09.007.
    [22]
    MA Z, WU Y. Current status of liver failure treatment[J]. J Clin Hepatol, 2016, 32( 9): 1668- 1672. DOI: 10.3969/j.issn.1001-5256.2016.09.007.

    马臻, 乌云. 肝衰竭的治疗现状[J]. 临床肝胆病杂志, 2016, 32( 9): 1668- 1672. DOI: 10.3969/j.issn.1001-5256.2016.09.007.
    [23]
    XU SS, WEI XH, LIN W, et al. Clinical significance of platelet count and its dynamic change in patients with acute-on-chronic liver failure[J]. J Clin Hepatol, 2018, 34( 4): 810- 813. DOI: 10.3969/j.issn.1001-5256.2018.04.023.

    许姗姗, 韦新焕, 林伟, 等. 慢加急性肝衰竭患者血小板计数及其动态变化的临床意义[J]. 临床肝胆病杂志, 2018, 34( 4): 810- 813. DOI: 10.3969/j.issn.1001-5256.2018.04.023.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (42) PDF downloads(9) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return